Oxford begins first human trial of Bundibugyo Ebola vaccine, Germany treats infected US citizen

A crucial step in combating the ongoing Bundibugyo ebolavirus outbreak has been taken as the University of Oxford launches the first human trial of a new vaccine. The early-stage trial, named BD-Ebov, will evaluate the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford. Vaccinations are expected to commence in the coming weeks, pending regulatory approval.

The vaccine utilizes the same viral vector platform as the widely known Oxford/AstraZeneca COVID-19 shot. The Serum Institute of India is a key partner, having manufactured and stockpiled approximately 620,000 doses of the vaccine candidate and supplied 4,000 investigational doses for this initial study. This development follows the World Health Organization's recommendation in May to prioritize clinical evaluation of the ChAdOx1 BDBV vaccine alongside another candidate.

Preparations are also underway for further clinical studies in Uganda, facilitated through partnerships with local research institutions. The Coalition for Epidemic Preparedness Innovations (CEPI) is providing significant financial backing, initially investing up to $8.6 million for the vaccine's development. The ultimate goal is to ensure rapid and affordable vaccine supplies for affected countries.

In parallel, a US citizen infected with the Ebola virus in the Democratic Republic of Congo has been admitted to Frankfurt University Hospital in Germany for treatment. This case highlights the international reach of the outbreak and the global efforts to manage and contain the disease.